- Home
- SCYX vs CASI Comparison
SCYX vs CASI Comparison
Compare SCYX & CASI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SCYX
- CASI
- Stock Information
- Founded
- SCYX 1999
- CASI 1991
- Country
- SCYX United States
- CASI China
- Employees
- SCYX N/A
- CASI N/A
- Industry
- SCYX Biotechnology: Pharmaceutical Preparations
- CASI Biotechnology: Pharmaceutical Preparations
- Sector
- SCYX Health Care
- CASI Health Care
- Exchange
- SCYX Nasdaq
- CASI Nasdaq
- Market Cap
- SCYX 34.9M
- CASI 35.8M
- IPO Year
- SCYX 2014
- CASI 1996
- Fundamental
- Price
- SCYX $1.10
- CASI $2.09
- Analyst Decision
- SCYX
- CASI Strong Buy
- Analyst Count
- SCYX 0
- CASI 1
- Target Price
- SCYX N/A
- CASI $4.00
- AVG Volume (30 Days)
- SCYX 204.1K
- CASI 82.7K
- Earning Date
- SCYX 11-05-2025
- CASI 11-13-2025
- Dividend Yield
- SCYX N/A
- CASI N/A
- EPS Growth
- SCYX N/A
- CASI N/A
- EPS
- SCYX N/A
- CASI N/A
- Revenue
- SCYX $3,257,000.00
- CASI $31,564,000.00
- Revenue This Year
- SCYX $422.61
- CASI N/A
- Revenue Next Year
- SCYX $240.56
- CASI N/A
- P/E Ratio
- SCYX N/A
- CASI N/A
- Revenue Growth
- SCYX N/A
- CASI 36.64
- 52 Week Low
- SCYX $0.66
- CASI $1.09
- 52 Week High
- SCYX $1.66
- CASI $7.50
- Technical
- Relative Strength Index (RSI)
- SCYX 71.20
- CASI 47.18
- Support Level
- SCYX $0.81
- CASI $2.18
- Resistance Level
- SCYX $1.31
- CASI $2.49
- Average True Range (ATR)
- SCYX 0.07
- CASI 0.18
- MACD
- SCYX 0.03
- CASI -0.05
- Stochastic Oscillator
- SCYX 58.33
- CASI 7.70
About SCYX SCYNEXIS Inc.
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.
About CASI CASI Pharmaceuticals Inc.
CASI Pharmaceuticals Inc is a biopharmaceutical company that focuses on commercializing therapeutics and pharmaceutical products. The products include injections for patients who are suffering from leukemias and lymphomas. The EVOMELA injection is used as a conditioning treatment before autologous stem cell transplant for patients with multiple myeloma. The company products include CID-103, CNCT19, EVOMELA, MARQIBO, ZEVALIN, ENMD-2076 and others. The majority of the revenue is generated from the product sales of EVOMELA.